A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of APP13007 to Treat Inflammation and Pain After Cataract Surgery

NCT04089735 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

165

Enrollment

INDUSTRY

Sponsor class

Conditions

Ocular Inflammation and Pain After Cataract Surgery

Interventions

DRUG: APP13007, 0.05%
DRUG: APP13007, 0.1%
DRUG: APP13007 Placebo, 0.05%
DRUG: APP13007 Placebo, 0.1%

Sponsor

Formosa Pharmaceuticals, Inc.